Summary & Overview
HCPCS Q9999: Injection, ustekinumab-aauz (Otulfi), 1 mg
HCPCS Level II code Q9999 designates the biosimilar injection ustekinumab-aauz (Otulfi) in a 1 mg unit. This HCPCS code is used to bill for the biologic agent when administered as an injectable therapy and is relevant to dermatology, gastroenterology, and rheumatology practices that use ustekinumab-class agents for immune-mediated inflammatory diseases. Nationally, accurate coding for biosimilars affects claims processing, drug utilization tracking, and payer coverage decisions for high-cost biologics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and billing implications for administering a unit-dose biologic, typical sites of service, and what to expect in payer coverage patterns. The publication also outlines benchmarks, common modifiers used in billing, and policy considerations affecting biosimilar adoption and reimbursement. The content is intended to help coding and billing professionals, practice managers, and policy analysts understand the role of Q9999 in claims submission and programmatic reporting for injectable biologic therapies.
Billing Code Overview
HCPCS Level II code Q9999 represents Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg. This code describes a single milligram unit of the biologic biosimilar ustekinumab-aauz (brand name Otulfi) intended for parenteral administration.
Service Type: Injectable biologic therapy
Typical Site of Service: Outpatient infusion/clinic or physician office for subcutaneous or intravenous administration, depending on clinical protocols and product labeling.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate to severe plaque psoriasis or psoriatic arthritis who qualifies for biologic therapy with ustekinumab biosimilar (Q9999). The patient has previously failed or had inadequate response to topical therapies, phototherapy, or conventional systemic agents (for example methotrexate or cyclosporine) or has contraindications to those therapies. The clinical workflow begins with a specialist visit (dermatology or rheumatology) confirming diagnosis and documenting prior therapies, comorbidities, and baseline labs (CBC, CMP, tuberculosis screening). The provider documents the weight-based or fixed dosing plan and orders the medication. The medication is prepared and administered by clinical staff in an outpatient infusion/injection suite or office procedure room. Post-injection, the patient is observed briefly for immediate hypersensitivity reactions and discharged with follow-up arranged with the prescribing specialist. Documentation includes indication, dose (mg), lot number, route (subcutaneous), injection site, consent, and any immediate adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) | Use when none of the listed special circumstances apply. |